Thymosin beta-4 promotes cardiac repair after myocardial infarction

Nature·2008·Bock-Marquette I, Saxena A, White MD, et al.·Nature

This study examined thymosin beta-4 (the parent molecule of TB-500) in a mouse model of myocardial infarction. Treatment promoted cardiomyocyte survival and improved cardiac function, associated with activation of survival pathways and reduction of inflammatory damage in cardiac tissue.

Why this research is interesting

This study is frequently cited in discussions about TB-500 and thymosin beta-4. It provides a biological rationale for investigating the peptide in cardiac repair contexts and illustrates the type of preclinical evidence that exists.

What the research says

In a mouse model of heart attack, thymosin beta-4 treatment improved survival of cardiac muscle cells and preserved heart function. The authors identified specific intracellular signaling pathways activated by the peptide.

What the evidence shows

This is an animal study in mice. While published in a high-impact journal, it represents preclinical research and does not demonstrate clinical efficacy in humans.

What remains uncertain

Whether these cardiac effects translate to human patients is unknown. No human clinical trials of thymosin beta-4 for cardiac repair have been completed. The doses, route, and timing used in the animal model may not correspond to human therapeutic scenarios.